The FDA on July 30, 2024, approved DARZALEX FASPRO® in combination with Bortezomib, Lenalidomide, and Dexamethasone for induction and consolidation in patients with newly diagnosed Multiple Myeloma who are eligible for Autologous Stem Cell Transplant (ASCT). DARZALEX FASPRO® is a product of Janssen Research & Development, LLC.
Bottom Ad
Advertisement
Subscribe
